EUVIMEDEUVIMED entdecken
Crossref

Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors

Moran Gvili Perelman, Rafael Y Brzezinski, Sheizaf Gefen, Roei Merin, Mor Miodovnik, Ari Raphael, Ido Wolf, Anna Rozenfeld Hemed, Maxim Perelman, Moaad Slieman, Shafik Khoury, Ofer Havakuk und 4 weitere

Supportive Care in Cancer · 2026-11 · 34 (11)

DOI: 10.1007/s00520-026-11366-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 26.10.2026. Verfasst von Moran Gvili Perelman und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Tel-Aviv Sourasky University Medical Center, 6 Weizmann Street, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Adrenergic beta-1 Receptor Antagonists, Cardiovascular Diseases. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immune checkpoint inhibitors (ICIs) have revolutionized cancer care and prognosis. Beta-adrenergic activation contributes to cancer initiation and progression. While non-selective beta-blockers were found to improve the efficacy of ICIs therapy, the role of beta-1 (β1)-selective beta-blocker (β_1B) is unknown. We aimed to evaluate the association between baseline selective β1-blocker therapy and all-cause mortality and cardiovascular immune-related adverse events (CV irAEs) among patients treated with ICIs.

Methods

We performed a retrospective single-center study including patients diagnosed with cancer and treated with ICIs therapy.

Results

Among 2409 patients, 591 (25%) were pretreated with β_1B. Patients in the β_1B group were older (72 ± 9 vs. 64 ± 13 years, p < 0.001) with a higher prevalence of cardiac risk factors and CV diseases including ischemic heart disease (40% vs. 8%, p < 0.001), heart failure (HF) (9% vs. 2%, p < 0.001) and atrial fibrillation (AF) (15% vs. 3%, p < 0.001). Patients pretreated with β_1B showed significantly increased all-cause mortality (68% vs. 57%, p < 0.001) and CV irAEs (14% vs. 7%, p < 0.001), mainly HF (7% vs. 3%, p < 0.001) and AF (7% vs. 3%, p < 0.001). In a multivariate analysis, β_1B remained a strong independent predictor for all-cause mortality (Hazard Ratio (HR) 1.21 [95% CI 1.05–1.39]), p = 0.010), however, not for CV irAEs (HR 1.22 [95% CI = 0.84–1.77], p = 0.290). The association between baseline selective β1-blocker treatment and increased all-cause mortality was consistent among patients with or without baseline CV disease.

Conclusions

Baseline β_1B therapy may be an independent predictor of increased all-cause mortality in patients treated with ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsAdrenergic beta-1 Receptor AntagonistsCardiovascular DiseasesHumansRetrospective StudiesFemaleMalePrognosisMiddle AgedAgedAged, 80 and overHeart Disease Risk Factors

Stichwörter der Autor:innen

Beta 1-selectiveBeta-blockersCardiooncologyCardiotoxicityICIsImmunotherapy

Substanzen

Immune Checkpoint InhibitorsAdrenergic beta-1 Receptor Antagonists

Autor:innen und Institutionen

  • Division of Cardiology, Tel-Aviv Sourasky University Medical Center, 6 Weizmann Street, Tel Aviv, Israel.
  • Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Division of Oncology, Tel-Aviv Sourasky University Medical Center, Tel Aviv, Israel.
  • Internal Medicine T, Tel-Aviv Sourasky University Medical Center, Tel Aviv, Israel.
  • Internal Medicine T, Chaim Sheba Medical Center, Ramat-Gan, Israel.
  • Division of Cardiology, Tel-Aviv Sourasky University Medical Center, 6 Weizmann Street, Tel Aviv, Israel. michallp@tlvmc.gov.il.

Zitieren

APA

Perelman, M. G., Brzezinski, R. Y., Gefen, S., Merin, R., Miodovnik, M., Raphael, A., Wolf, I., Hemed, A. R., Perelman, M., Slieman, M., Khoury, S., Havakuk, O., Topilsky, Y., Banai, S., Leshem, Y., & Laufer-Perl, M. (2026). Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11366-7

Vancouver

Perelman MG, Brzezinski RY, Gefen S, Merin R, Miodovnik M, Raphael A, et al. Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11366-7

BibTeX
@article{Perelman2026,
  author = {Perelman, Moran Gvili and Brzezinski, Rafael Y and Gefen, Sheizaf and Merin, Roei and Miodovnik, Mor and Raphael, Ari and Wolf, Ido and Hemed, Anna Rozenfeld and Perelman, Maxim and Slieman, Moaad and Khoury, Shafik and Havakuk, Ofer and Topilsky, Yan and Banai, Shmuel and Leshem, Yasmin and Laufer-Perl, Michal},
  title = {Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {11},
  doi = {10.1007/s00520-026-11366-7}
}
Kostenlos starten →